The StreetInsider August 27, 2012
Sarepta Therapeutics (SRPT) Higher on Barron's article.
Overall Analyst Rating:
BUY (Up Up)
Sarepta Therapeutics (Nasdaq: SRPT) continues its recent ramp following a positive piece in Barron's over the weekend highlighting the company's treatment for Duchenne muscular dystrophy.
While shares are up from $4 to $10 recently, analysts argue they could go as high as $26 as peak sales of eteplirsen "could conservatively reach $600 million in the U.S. alone."